

Krzysztof Jamroziak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1056741/publications.pdf>

Version: 2024-02-01

199
papers

3,020
citations

201385

27
h-index

223531

46
g-index

215
all docs

215
docs citations

215
times ranked

4146
citing authors

#	ARTICLE	IF	CITATIONS
1	Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. <i>New England Journal of Medicine</i> , 2021, 385, 46-58.	13.9	268
2	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. <i>Nature Communications</i> , 2018, 9, 556.	5.8	188
3	Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. <i>European Journal of Haematology</i> , 2004, 72, 314-321.	1.1	172
4	Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). <i>Blood</i> , 2006, 108, 473-479.	0.6	119
5	Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study). <i>Journal of Clinical Oncology</i> , 2010, 28, 1863-1869.	0.8	86
6	Pharmacogenomics ofMDR1/ABCB1Gene: the Influence on Risk and Clinical Outcome of Haematological Malignancies. <i>Hematology</i> , 2004, 9, 91-105.	0.7	74
7	Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. <i>Blood</i> , 2007, 109, 3672-3675.	0.6	70
8	Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy. <i>Oncotarget</i> , 2016, 7, 56726-56736.	0.8	58
9	<sc><i>TERT</i></sc> gene harbors multiple variants associated with pancreatic cancer susceptibility. <i>International Journal of Cancer</i> , 2015, 137, 2175-2183.	2.3	57
10	ABO blood groups and pancreatic cancer risk and survival: Results from the PANcreatic Disease ReseArch (PANDoRA) consortium. <i>Oncology Reports</i> , 2013, 29, 1637-1644.	1.2	55
11	The experimental and numerical analysis of the ballistic resistance of polymer composites. <i>Composites Part B: Engineering</i> , 2017, 113, 24-30.	5.9	50
12	Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 1949-1958.	0.6	48
13	Proapoptotic activity of alemtuzumab alone and in combination with rituximab or purine nucleoside analogues in chronic lymphocytic leukemia cells. <i>Leukemia and Lymphoma</i> , 2005, 46, 87-100.	0.6	46
14	ABCB1 gene polymorphisms and haplotype analysis in colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2009, 24, 895-905.	1.0	45
15	Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. <i>Digestive and Liver Disease</i> , 2013, 45, 95-99.	0.4	45
16	Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. <i>Oncotarget</i> , 2016, 7, 57011-57020.	0.8	41
17	Current and Emerging Treatments for Chronic Lymphocytic Leukaemia. <i>Drugs</i> , 2009, 69, 2415-2449.	4.9	39
18	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015, 6, 7539.	5.8	38

#	ARTICLE	IF	CITATIONS
19	MDR1 (ABCB1) gene polymorphism C3435T is associated with P-glycoprotein activity in B-cell chronic lymphocytic leukemia. <i>Pharmacological Reports</i> , 2006, 58, 720-8.	1.5	38
20	Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. <i>International Journal of Cancer</i> , 2019, 144, 1275-1283.	2.3	36
21	Real-life comparison of severe vascular events and other non-hematological complications in patients with chronic myeloid leukemia undergoing second-line nilotinib or dasatinib treatment. <i>Leukemia and Lymphoma</i> , 2015, 56, 2309-2314.	0.6	34
22	Efficacy and toxicity of compassionate ibrutinib use in relapsed/refractory chronic lymphocytic leukemia in Poland: analysis of the Polish Adult Leukemia Group (PALG). <i>Leukemia and Lymphoma</i> , 2017, 58, 2485-2488.	0.6	34
23	Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. <i>Leukemia Research</i> , 2009, 33, 332-335.	0.4	33
24	Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. <i>Leukemia</i> , 2019, 33, 2324-2330.	3.3	33
25	Insights on Multiple Myeloma Treatment Strategies. <i>HemaSphere</i> , 2019, 3, e163.	1.2	33
26	CD38 Gene Polymorphisms Contribute to Genetic Susceptibility to B-Cell Chronic Lymphocytic Leukemia: Evidence from Two Case-Control Studies in Polish Caucasians. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 945-953.	1.1	32
27	Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2019, 11, 1834.	1.7	32
28	Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. <i>Journal of Medical Genetics</i> , 2021, 58, 369-377.	1.5	31
29	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. <i>International Journal of Cancer</i> , 2015, 136, E351-8.	2.3	30
30	Activity of cladribine combined with cyclophosphamide in frontline therapy for chronic lymphocytic leukemia with 17p13.1/TP53 deletion. <i>Cancer</i> , 2009, 115, 94-100.	2.0	26
31	Polymorphism of CD44 Influences the Efficacy of CD34+ Cells Mobilization in Patients with Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 986-991.	2.0	25
32	Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. <i>Haematologica</i> , 2012, 97, 428-436.	1.7	24
33	Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. <i>Leukemia</i> , 2015, 29, 748-751.	3.3	24
34	No Influence of 3435C>T ABCB1 (MDR1) Gene Polymorphism on Risk of Adult Acute Myeloid Leukemia and P-glycoprotein Expression in Blast Cells. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 707-711.	1.0	23
35	Genome-wide scan of long noncoding RNA single nucleotide polymorphism and pancreatic cancer susceptibility. <i>International Journal of Cancer</i> , 2021, 148, 2779-2788.	2.3	23
36	Ballistic Impact Resistance of Bulletproof Vest Inserts Containing Printed Titanium Structures. <i>Metals</i> , 2021, 11, 225.	1.0	22

#	ARTICLE	IF	CITATIONS
37	Distribution of allelic variants of functional C3435T polymorphism of drug transporter MDR1 gene in a sample of Polish population. <i>Polish Journal of Pharmacology</i> , 2002, 54, 495-500.	0.3	22
38	Genetic polymorphisms in the proximal IL-10 promoter and susceptibility to non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2235-2238.	0.6	21
39	Analysis of ballistic resistance of composites based on EN AC-44200 aluminum alloy reinforced with Al ₂ O ₃ particles. <i>Composite Structures</i> , 2018, 201, 834-844.	3.1	21
40	Evaluation of circulating endothelial cells as noninvasive marker of angiogenesis in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 62-67.	0.6	20
41	Poor prognosis of <sc>H</sc>odgkin variant of <sc>R</sc>ichter transformation in chronic lymphocytic leukemia treated with cladribine. <i>British Journal of Haematology</i> , 2012, 158, 286-288.	1.2	20
42	Lack of Replication of Seven Pancreatic Cancer Susceptibility Loci Identified in Two Asian Populations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 320-323.	1.1	20
43	Genome-wide association study identifies an early onset pancreatic cancer risk locus. <i>International Journal of Cancer</i> , 2020, 147, 2065-2074.	2.3	20
44	Common genetic variation at 15q25.2 impacts on chronic lymphocytic leukaemia risk. <i>British Journal of Haematology</i> , 2011, 154, 229-233.	1.2	19
45	Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. <i>British Journal of Haematology</i> , 2012, 158, 805-809.	1.2	19
46	Ballistic Head Protection in the Light of Injury Criteria in the Case of the Wz.93 Combat Helmet. <i>Applied Sciences (Switzerland)</i> , 2019, 9, 2702.	1.3	18
47	Current Treatment of Chronic Lymphocytic Leukemia. <i>Current Treatment Options in Oncology</i> , 2017, 18, 5.	1.3	17
48	Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. <i>Carcinogenesis</i> , 2018, 39, 360-367.	1.3	16
49	Improved manufacturing performance of a new antifriction composite parts based on copper. <i>Engineering Failure Analysis</i> , 2018, 91, 225-233.	1.8	16
50	Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma. <i>Advances in Medical Sciences</i> , 2019, 64, 349-355.	0.9	16
51	Assessment of the Impact Resistance of a Composite Material with EN AW-7075 Matrix Reinforced with \pm -Al ₂ O ₃ Particles Using a 7.62 Å— 39 mm Projectile. <i>Materials</i> , 2020, 13, 769.	1.3	16
52	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMENSE consortium and meta-analysis. <i>Oncotarget</i> , 2016, 7, 59029-59048.	0.8	16
53	Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. <i>Pharmacological Reports</i> , 2005, 57, 882-8.	1.5	16
54	Finite element modeling of ballistic inserts containing aramid fabrics under projectile impact conditions – Comparison of methods. <i>Composite Structures</i> , 2022, 294, 115752.	3.1	16

#	ARTICLE	IF	CITATIONS
55	The Role of Complement Activating Collectins and Associated Serine Proteases in Patients With Hematological Malignancies, Receiving High-Dose Chemotherapy, and Autologous Hematopoietic Stem Cell Transplantations (Auto-HSCT). <i>Frontiers in Immunology</i> , 2018, 9, 2153.	2.2	15
56	Associations of ficolins and mannose-binding lectin with acute myeloid leukaemia in adults. <i>Scientific Reports</i> , 2020, 10, 10561.	1.6	15
57	Comparison of Numerical Simulation Techniques of Ballistic Ceramics under Projectile Impact Conditions. <i>Materials</i> , 2022, 15, 18.	1.3	15
58	Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (Review). <i>International Journal of Oncology</i> , 2011, 40, 625-38.	1.4	14
59	Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. <i>Leukemia</i> , 2012, 26, 1419-1422.	3.3	14
60	An identification of nonlinear dissipative properties of constructional materials at dynamical impact loads conditions. <i>Meccanica</i> , 2014, 49, 1955-1965.	1.2	14
61	Numerical and Experimental Studies of the ÅK Type Shaped Charge. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 6742.	1.3	14
62	Friction Mechanism Features of the Nickel-Based Composite Antifriction Materials at High Temperatures. <i>Coatings</i> , 2020, 10, 454.	1.2	14
63	Associations of Ficolins With Hematological Malignancies in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantations. <i>Frontiers in Immunology</i> , 2020, 10, 3097.	2.2	14
64	Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. <i>Carcinogenesis</i> , 2021, 42, 1037-1045.	1.3	14
65	Richter's Syndrome in the Brain First Manifested as an Ischaemic Stroke. <i>Leukemia and Lymphoma</i> , 2004, 45, 1261-1267.	0.6	13
66	Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the <sc>IMME</sc><sc>SE</sc> consortium. <i>British Journal of Haematology</i> , 2012, 157, 331-338.	1.2	13
67	Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associations—An Extensive Replication of the Associations from the Candidate Gene Era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 670-674.	1.1	13
68	Experimental analysis of puncture resistance of aramid laminates on styrene-butadiene-styrene and epoxy resin matrix for ballistic applications. <i>Archives of Civil and Mechanical Engineering</i> , 2019, 19, 1327-1337.	1.9	13
69	Intestinal amyloidosis: Clinical manifestations and diagnostic challenge. <i>Advances in Clinical and Experimental Medicine</i> , 2021, 30, 563-570.	0.6	13
70	Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. <i>Journal of Clinical Medicine</i> , 2021, 10, 2800.	1.0	13
71	Human leukocyte antigens HLA DRB1 influence clinical outcome of chronic lymphocytic leukemia. <i>Haematologica</i> , 2007, 92, 710-711.	1.7	12
72	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. <i>Endocrine-Related Cancer</i> , 2015, 22, 545-559.	1.6	11

#	ARTICLE	IF	CITATIONS
73	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. <i>British Journal of Haematology</i> , 2018, 183, 375-384.	1.2	11
74	<p>Immunochemotherapy for Richter syndrome: current insights</p>. <i>ImmunoTargets and Therapy</i> , 2019, Volume 8, 1-14.	2.7	11
75	Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMENSE study. <i>Leukemia and Lymphoma</i> , 2019, 60, 1803-1811.	0.6	11
76	X-ray Computed Tomography for the Development of Ballistic Composite. <i>Materials</i> , 2020, 13, 5566.	1.3	11
77	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
78	Do polymorphisms in ABC transporter genes influence risk of childhood acute lymphoblastic leukemia?. <i>Leukemia Research</i> , 2008, 32, 1173-1175.	0.4	10
79	Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia. <i>Blood Cells, Molecules, and Diseases</i> , 2015, 54, 139-143.	0.6	10
80	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2016. <i>Acta Haematologica Polonica</i> , 2016, 47, 39-85.	0.1	10
81	Metallographic analysis of piercing armor plate by explosively formed projectiles. <i>Archives of Civil and Mechanical Engineering</i> , 2018, 18, 1686-1697.	1.9	10
82	Genetically determined telomere length and multiple myeloma risk and outcome. <i>Blood Cancer Journal</i> , 2021, 11, 74.	2.8	10
83	Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. <i>Frontiers in Genetics</i> , 2021, 12, 693933.	1.1	10
84	Critical to Quality Factors of Engineering Design Process of Armoured Vehicles. <i>Solid State Phenomena</i> , 0, 165, 280-284.	0.3	9
85	The Analysis of Energy Consumption of a Ballistic Shields in Simulation of Mobile Cellular Automata. <i>Advanced Materials Research</i> , 2014, 1036, 680-685.	0.3	9
86	Cereblon expression predicts clinical response in chronic lymphocytic leukemia treated with a thalidomide/fludarabine regimen. <i>Leukemia and Lymphoma</i> , 2015, 56, 808-810.	0.6	9
87	Analysis of Material Punching Including a Rotational Speed of the Projectile. <i>Solid State Phenomena</i> , 2015, 220-221, 571-576.	0.3	8
88	Numerical Modeling of the Microstructure of Ceramic-Metallic Materials. <i>Procedia Engineering</i> , 2017, 199, 1495-1500.	1.2	8
89	Identification of miRSNPs associated with the risk of multiple myeloma. <i>International Journal of Cancer</i> , 2017, 140, 526-534.	2.3	8
90	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. <i>Anticancer Research</i> , 2020, 40, 4059-4066.	0.5	8

#	ARTICLE	IF	CITATIONS
91	Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. <i>Frontiers in Oncology</i> , 2021, 11, 771312.	1.3	8
92	Hodgkin's variant of Richter's transformation during ibrutinib therapy in a series of <scp>CLL</scp> patients; the Polish Adult Leukemia Group report (<scp>PALG</scp>). <i>European Journal of Haematology</i> , 2018, 100, 389-391.	1.1	7
93	Differential Function of a Novel Population of the CD19+CD24hiCD38hi Bregs in Psoriasis and Multiple Myeloma. <i>Cells</i> , 2021, 10, 411.	1.8	7
94	Structure and Properties of the New Antifriction Composite Materials for High-Temperature Friction Units. <i>Lecture Notes in Mechanical Engineering</i> , 2019, , 628-637.	0.3	7
95	Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG). <i>Advances in Clinical and Experimental Medicine</i> , 2019, 28, 1051-1057.	0.6	7
96	Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG). <i>Anticancer Research</i> , 2018, 38, 3025-3030.	0.5	7
97	Analysis using the finite element method of a novel modular system of additively manufactured osteofixation plates for mandibular fractures - A preclinical study. <i>Biomedical Signal Processing and Control</i> , 2021, 65, 102342.	3.5	6
98	Cladribine in Weekly Versus Daily Schedule for Untreated Active Hairy Cell Leukemia: Final Report of Polish Adult Leukemia Group (PALG) Prospective, Randomized, Multicenter Trial.. <i>Blood</i> , 2006, 108, 2485-2485.	0.6	6
99	Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 558.	1.7	6
100	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego na rok 2012. <i>Acta Haematologica Polonica</i> , 2012, 43, 7-47.	0.1	5
101	Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a caseâ€“control study in the context of the IMMENSE consortium. <i>Journal of Human Genetics</i> , 2013, 58, 155-159.	1.1	5
102	Long-term results of the Polish Adult Leukemia Group PALG-CLL2 phase III randomized study comparing cladribine-based combinations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 606-610.	0.6	5
103	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrzacji plazmocytoowych na rok 2017. <i>Acta Haematologica Polonica</i> , 2017, 48, 55-103.	0.1	5
104	Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDORA Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1349-1351.	1.1	5
105	Experimental and numerical analysis of aramid fiber laminates with DCPD resin matrix subjected to impact tests. <i>MATEC Web of Conferences</i> , 2017, 112, 04013.	0.1	5
106	Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 527 Patients From the Polish Adult Leukemia Group Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e283-e285.	0.2	5
107	Szczepienia ochronne u dorosÅ,ych chorych na nowotwory hematologiczne oraz u chorych z aspleniÄ... â€“ zalecenia PTHiT i sekcji do spraw zakaÅ¼eÅ,, PALG. <i>Acta Haematologica Polonica</i> , 2018, 49, 93-101.	0.1	5
108	Analysis of heat exchange in the powertrain of a road vehicle with a retarder. <i>Eksplotacja I Niezawodnosc</i> , 2019, 21, 577-584.	1.1	5

#	ARTICLE	IF	CITATIONS
109	A polygenic risk score for multiple myeloma risk prediction. <i>European Journal of Human Genetics</i> , 2022, 30, 474-479.	1.4	5
110	Calculations with the Finite Element Method During the Design Ballistic Armour. <i>Lecture Notes in Mechanical Engineering</i> , 2017, , 451-459.	0.3	4
111	Methods of Identification of Definite Degenerated and Nonlinear Dynamic System Using Specially Programmed Nonharmonic Enforce. <i>Journal of Dynamic Systems, Measurement and Control, Transactions of the ASME</i> , 2017, 139, .	0.9	4
112	Association between the CEBPA and c-MYC genes expression levels and acute myeloid leukemia pathogenesis and development. <i>Medical Oncology</i> , 2020, 37, 109.	1.2	4
113	Clonal Evolution of Multiple Myeloma – Clinical and Diagnostic Implications. <i>Diagnostics</i> , 2021, 11, 1534.	1.3	4
114	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 2342-2345.	1.1	4
115	Cereblon (CRBN) Gene Polymorphisms Predict Clinical Response and Progression-Free Survival in Multiple Myeloma Patients Treated with Lenalidomide: A Pharmacogenetic Study of Immense Consortium. <i>Blood</i> , 2014, 124, 3628-3628.	0.6	4
116	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytowych na rok 2018/2019. <i>Acta Haematologica Polonica</i> , 2018, 49, 157-206.	0.1	4
117	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej, białej, limfocytowej w 2014 r. – raport Grupy Roboczej PTHiT oraz PALG – CLL. <i>Acta Haematologica Polonica</i> , 2014, 45, 221-239.	0.1	3
118	Identification of a Subsystem Located in The Complex Dynamical Systems Subjected to Random Loads. <i>Journal of Computational and Nonlinear Dynamics</i> , 2017, 12, .	0.7	3
119	The analysis of structure of the repaired freight wagon. <i>AIP Conference Proceedings</i> , 2018, , .	0.3	3
120	Experimental and metallographic analysis of the energy-absorbing shield subjected to the EFP impact. <i>AIP Conference Proceedings</i> , 2019, , .	0.3	3
121	Expression level of CEBPA gene in acute lymphoblastic leukemia individuals. <i>Scientific Reports</i> , 2019, 9, 15640.	1.6	3
122	Hodgkin lymphoma transformation of chronic lymphocytic leukemia – A real life data from the Polish Lymphoma Research Group. <i>Hematological Oncology</i> , 2019, 37, 383-391.	0.8	3
123	Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. <i>Leukemia and Lymphoma</i> , 2020, 61, 699-706.	0.6	3
124	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
125	Common gene variants within 3' untranslated regions as modulators of multiple myeloma risk and survival. <i>International Journal of Cancer</i> , 2021, 148, 1887-1894.	2.3	3
126	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , 2021, 149, 327-336.	2.3	3

#	ARTICLE	IF	CITATIONS
127	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	0.6	3
128	Real-Life Comparison Of Severe Vascular Events and Other Non-Hematological Complications In CML Patients Treated With Second Line Nilotinib Or Dasatinib. <i>Blood</i> , 2013, 122, 1491-1491.	0.6	3
129	The impact of cytogenetic evolution and acquisition of del(17p) on the prognosis of multiple myeloma patients. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 483-491.	0.3	3
130	Safe administration of rituximab in patients with chronic lymphocytic leukemia and a history of obinutuzumab-associated anaphylaxis. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 494-495.	0.3	3
131	Harmonization of Flow Cytometric Minimal Residual Disease Assessment in Multiple Myeloma in Centers of Polish Myeloma Consortium. <i>Diagnostics</i> , 2021, 11, 1872.	1.3	3
132	Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing. <i>Biomedicines</i> , 2022, 10, 1674.	1.4	3
133	The Analysis of Hydrogen Absorption by the Fatigue Crack in Changeable Loaded Structure. <i>Advanced Materials Research</i> , 2014, 1036, 541-546.	0.3	2
134	Analysis of Non-Classical Models which Have been Subjected to Percussive Loads Using Equations of Energy and Power. <i>Advanced Materials Research</i> , 2014, 1036, 608-613.	0.3	2
135	Numerical Analysis of the Dynamic Impact of a Gun Barrel During Firing. <i>Advances in Intelligent Systems and Computing</i> , 2019, , 162-174.	0.5	2
136	Concept of a gun barrel based on the layer composite reinforced with continuous filament. <i>AIP Conference Proceedings</i> , 2019, , .	0.3	2
137	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. <i>Advances in Medical Sciences</i> , 2020, 65, 371-377.	0.9	2
138	Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group. <i>Advances in Medical Sciences</i> , 2020, 65, 429-436.	0.9	2
139	Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib. <i>European Journal of Haematology</i> , 2021, 106, 320-326.	1.1	2
140	Rapamycin, Inhibitor of Mtor Kinase, Sensitizes Leukemia Cells to Fludarabine-Induced Apoptosis, but Protects Survival of Normal Lymphocytes.. <i>Blood</i> , 2004, 104, 4497-4497.	0.6	2
141	Structure Formation in Antifriction Composites with a Nickel Matrix and Its Effect on Properties. <i>Materials</i> , 2022, 15, 3404.	1.3	2
142	Variants of CD38 gene and lipid metabolism: A link in chronic lymphocytic leukemia?. <i>Leukemia Research</i> , 2012, 36, 1227-1228.	0.4	1
143	Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukaemia treated with cladribine - Response to Jamroziak <i>et al</i> . <i>British Journal of Haematology</i> , 2012, 158, 289-289.	1.2	1
144	CD38 gene polymorphisms and genetic predisposition to multiple myeloma. <i>Acta Haematologica Polonica</i> , 2013, 44, 58-62.	0.1	1

#	ARTICLE	IF	CITATIONS
145	Parametric Identification of the Degenerate Model with a Dissipative-Elastic Element Dispersing Impact Energy. <i>Solid State Phenomena</i> , 0, 220-221, 213-217.	0.3	1
146	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej, białaczki limfocytowej w 2016 r – Raport Grupy Roboczej PTHiT i PALG-CLL. <i>Acta Haematologica Polonica</i> , 2016, 47, 169-183.	0.1	1
147	Analiza skuteczności ibrutinibu w podgrupie chorych na przewlekłą, białaczkę limfocytową z delecją 17p: badanie obserwacyjne Polskiej Grupy ds. Leczenia Białaczek u Dorosłych (PALG). <i>Acta Haematologica Polonica</i> , 2017, 48, 330-337.	0.1	1
148	Analysis of purely harmonic vibrations in non-linear dynamic systems on the example of the non-linear degenerate system. <i>Procedia Engineering</i> , 2017, 199, 522-527.	1.2	1
149	Pharmacogenetic Analysis of Polymorphisms in Pharmacological Pathway of Vincristine, Doxorubicine and Dexamethasone (VAD Regimen) To Predict Response in Patients with Multiple Myeloma. <i>Blood</i> , 2005, 106, 104-104.	0.6	1
150	Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamide in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3). <i>Blood</i> , 2008, 112, 2103-2103.	0.6	1
151	A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis. <i>Blood</i> , 2013, 122, 1640-1640.	0.6	1
152	Rola idelalizybu w leczeniu chorych na przewlekłą, białaczkę limfocytową. <i>Hematologia</i> , 2017, 7, 217-230.0.0		1
153	Rola wenetoklaksu w leczeniu chorych na przewlekłą, białaczkę limfocytową. <i>Hematologia</i> , 2017, 8, 20-32.0.0		1
154	Powikłania autologicznego przeszczepienia krwiotwórczych komórek macierzystych u pacjentki z układową amyloidozą AL. <i>Hematologia</i> , 2020, 11, 50-57.	0.0	1
155	Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamide in Progressive Chronic Lymphocytic Leukemia: An Updated Report of Prospective PALG-CLL3 Study. <i>Blood</i> , 2006, 108, 2826-2826.	0.6	1
156	CD38 Gene Polymorphisms Contribute to Genetic Predisposition to B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 2007, 110, 491-491.	0.6	1
157	Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis: A Retrospective Analysis of 470 Patients from the Polish Adult Leukemia Group (PALG) Registry. <i>Blood</i> , 2016, 128, 1909-1909.	0.6	1
158	Znaczenie minimalnej choroby resztkowej w szpiczaku plazmocytowym – Stanowisko Polskiego Konsorcjum Szpiczakowego. <i>Hematologia</i> , 2018, 8, 246-254.	0.0	1
159	Praktyka kliniczna oceny minimalnej choroby resztkowej u chorych na szpiczaka plazmocytowego w Polsce: badanie ankietowe Polskiego Konsorcjum Szpiczakowego. <i>Hematologia</i> , 2018, 8, 239-245.	0.0	1
160	Diagnostyka i leczenie amyloidozy AL. <i>Hematologia</i> , 2018, 9, 181-195.	0.0	1
161	Zasady klasyfikacji i nazewnictwa amyloidoz. <i>Hematologia</i> , 2018, 9, 167-172.	0.0	1
162	Autologous stem cell transplantation in the treatment of multiple myeloma patients with 17p deletion. <i>Polish Archives of Internal Medicine</i> , 2020, 130, 106-111.	0.3	1

#	ARTICLE	IF	CITATIONS
163	Polymorphisms of the glucocorticoid receptor gene: impact on clinical outcome of multiple myeloma. <i>Comparative Clinical Pathology</i> , 2013, 22, 157-163.	0.3	0
164	Cereblon: molekularny cel leków immunomodulujących. <i>Acta Haematologica Polonica</i> , 2013, 44, 200-207.	0.1	0
165	Znaczenie bortezomibu w leczeniu szpiczaka plazmocytozowego u pacjentów z ryzykiem cytogenetycznym. <i>Acta Haematologica Polonica</i> , 2014, 45, 247-257.	0.1	0
166	Substytucja immunoglobulin u chorych na przewlekłą, białaczkę limfocytową i szpiczaka plazmocytozowego. <i>Acta Haematologica Polonica</i> , 2015, 46, 233-241.	0.1	0
167	Chosen Problems of Selection the Basic Chassis for the Special Purpose Body. <i>Solid State Phenomena</i> , 2015, 220-221, 829-832.	0.3	0
168	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytozowego oraz innych dyskracji plazmocytozowych na rok 2015. <i>Acta Haematologica Polonica</i> , 2015, 46, 159-211.	0.1	0
169	Iksazomib u chorych z nawrotowym lub opornym na leczenie szpiczakiem plazmocytozowym. <i>Acta Haematologica Polonica</i> , 2017, 48, 160-164.	0.1	0
170	High-dimensional Clonal Heterogeneity and Immune Landscape in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e28-e29.	0.2	0
171	Friction Films and Their Influence on the Antifriction Properties of New High-Temperature Nickel Composites. <i>Lecture Notes in Mechanical Engineering</i> , 2021, , 601-611.	0.3	0
172	Prompt Determination of the Mechanical Properties of Industrial Polypropylene Sandwich Pipes. <i>Materials</i> , 2021, 14, 2128.	1.3	0
173	Analysis of Common Single Nucleotide Polymorphisms in MDR1 Gene in Patients with Multiple Myeloma. <i>Blood</i> , 2004, 104, 4371-4371.	0.6	0
174	The VH3-21 Gene Status Correlates with Elevated β_2 -Microglobulin Serum Levels and Shorter Overall Survival of Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2005, 106, 4988-4988.	0.6	0
175	Inhibition of mTOR Kinase Pathway Selectively Sensitizes Acute Myeloid Leukemia Cells to Cytarabine-Induced Apoptosis. <i>Blood</i> , 2005, 106, 2474-2474.	0.6	0
176	Pharmacogenetics of Response to Glucocorticosteroids in Adults with Acute Lymphoblastic Leukemia. <i>Blood</i> , 2006, 108, 2609-2609.	0.6	0
177	Influence of High Expression of p73 and p53 Proteins on Clinical Outcome in Acute Myeloid Leukemia Patients. <i>Blood</i> , 2007, 110, 4306-4306.	0.6	0
178	Polymorphisms in CD31/PECAM-1 and CD38 Genes Are Associated with Susceptibility to Multiple Myeloma. <i>Blood</i> , 2008, 112, 5113-5113.	0.6	0
179	Clinical Relevance of Vascular Endothelial Growth Factor Type A (VEGFA) and VEGF Receptor Type 2 (VEGFR2) Gene Polymorphism In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 4467-4467.	0.6	0
180	Polymorphism Of CD44 Influences Efficacy Of CD34+Cells Mobilization In Patients With Hematological Malignancies. <i>Blood</i> , 2013, 122, 3270-3270.	0.6	0

#	ARTICLE	IF	CITATIONS
181	High Expression Of Cereblon (CRBN) Is Associated With Achievement Of Complete Response To Thalidomide Plus Fludarabine Regimen In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013, 122, 4934-4934.	0.6	0
182	Abstract 5078: Genome wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. , 2014, , .		0
183	Type 2 Diabetes-Related Variants Influence on the Risk of Developing Multiple Myeloma: Results from the Immense Consortium. <i>Blood</i> , 2014, 124, 2044-2044.	0.6	0
184	Impact of Drug Transporters ABCB1 and ABCG2 and Regulators of Xenobiotic Transport and Metabolism Pxr and CAR Gene Polymorphisms on Clinical Efficacy of Imatinib in Chronic Myeloid Leukemia (CML). <i>Blood</i> , 2014, 124, 5222-5222.	0.6	0
185	The International Multiple Myeloma Research (IMMEnSE) Consortium: Genetics of Multiple Myeloma Risk and Prognosis. <i>Blood</i> , 2014, 124, 3421-3421.	0.6	0
186	The Method of Determining Certain Parameters of Energy Absorption in Materials Under Complex Dynamic Excitations. <i>Springer Proceedings in Energy</i> , 2015, , 597-605.	0.2	0
187	Post- TM py w diagnostyce i leczeniu chorych na szpiczaka plazmocytowego. <i>Hematologia</i> , 2015, 6, 10-18.	0.0	0
188	Etiologia i patogeneza szpiczaka plazmocytowego. <i>Hematologia</i> , 2015, 6, 245-263.	0.0	0
189	Ocena stanu odżywienia pacjentów z nowotworami układu krwiotwórczego i chłonnego za pomocą... skali PG-SGA. <i>Hematologia</i> , 2017, 8, 105-112.	0.0	0
190	Rola daratumumabu w leczeniu chorych na nawrotowego i opornego szpiczaka plazmocytowego. <i>Hematologia</i> , 2018, 8, 255-264.	0.0	0
191	Znaczenie oceny minimalnej choroby resztkowej w amyloidozie AL. <i>Hematologia</i> , 2018, 9, 196-201.	0.0	0
192	Jak leczymy pacjenta z nowo rozpoznanej amyloidoz... w lekkich postaciach średniego ryzyka? Rola doksycykliny w terapii amyloidozy z zajęciem serca. <i>Hematologia</i> , 2018, 9, 245-253.	0.0	0
193	Doksycyklina w terapii amyloidozy układu oddechowego z zajęciem serca. <i>Hematologia</i> , 2018, 9, 202-207.	0.0	0
194	Ocena profilu korzyści i ryzyka leczenia idelalizybem u chorych na przewlekłą... białaczkę limfocytową... i chłoniaki nie-Hodgkina. <i>Hematologia</i> , 0, , .	0.0	0
195	Nowe terapie w leczeniu szpiczaka z wysokim ryzykiem cytogenetycznym. <i>Acta Haematologica Polonica</i> , 2018, 49, 102-111.	0.1	0
196	Qualitative Evaluation of Modeling the Aramid Fabric Elementary Cell in the Piercing Process with a 9Amm Full Metal Jacket Projectile. <i>Lecture Notes in Mechanical Engineering</i> , 2019, , 581-590.	0.3	0
197	Ibrutinib Therapy for Chronic Lymphocytic Leukemia Complicated with Secondary Serous Adenocarcinoma of the Peritoneum. <i>UHOD - Uluslararası Hematoloji-Onkoloji Dergisi</i> , 2019, 29, 186-189.	0.1	0
198	Wyzwania wczesnej diagnostyki szpiczaka plazmocytowego – algorytm diagnostyczny. <i>Acta Haematologica Polonica</i> , 2019, 50, 121-129.	0.1	0

#	ARTICLE	IF	CITATIONS
199	Rola brentuksymabu vedotin w leczeniu chorych na opornego/nawrotowego chłoniaka Hodgkina na przykładzie dwóch opisów przypadków. Hematologia, 2019, 10, 7-16.	0.0	0